Drug Profile
Vusolimogene oderparepvec - Replimune
Alternative Names: Recombinant Herpes Simplex Virus Type 1 - hGM CSF/GALV-GP-R-; RP 1Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Replimune
- Developer Bristol-Myers Squibb; Regeneron Pharmaceuticals; Replimune
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 08 Feb 2024 Replimune plans a phase III trial for Malignant melanoma (Second-line therapy or greater, Combination therapy) (Intratumoural) in the second half of 2024
- 08 Feb 2024 Replimune announces intention to submit Biologics License Application (BLA) for RP1 in Malignant melanoma, in the second half of 2024
- 22 Jan 2024 Replimune plans a phase I trial for Malignant melanoma in USA (Parenteral, Injection) in January 2024 (NCT06216938)